YEKATERINA TATARCHUK: Open Payments
NPI 1336374412 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$674 in 24 payments from 8 companies in 2025. Trend: 2023 $200 · 2024 $573 · 2025 $674
Food & beverage: $674
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $160 |
| Janssen Pharmaceuticals, Inc | 4 | $139 |
| ABBVIE INC. | 4 | $104 |
| E.R. Squibb & Sons, L.L.C. | 3 | $82 |
| Alkermes, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
Products named: INGREZZA, INVEGA SUSTENNA, VRAYLAR, COBENFY, CAPLYTA, UZEDY, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across PA — which companies pay providers there.
